People are expected to live longer than ever before because of access to quality healthcare. Yet, improvements to human healthspan have regrettably not kept pace with expectations. Increasingly, research has pointed to the ageing process itself as a strong driver of debilitating diseases like cancer and Alzheimer's Disease, often seen in people living their golden years. With this knowledge, new therapeutic approaches have emerged to treat the mechanisms of ageing as a means to prevent age-associated diseases.
In this week's #HealthyLongevity #webinar, Dr James Peyer, Chief Executive Officer and Co-Founder of Cambrian Biopharma, takes viewers through Cambrian's vision and philosophy and their revolutionary approaches to discover, develop and commercialise new solutions to target ageing and diseases, and promote healthy longevity.
Register for upcoming webinar sessions at [ Ссылка ]
#NUSMedicine #webinarseries
Reference:
Source of the closing video: [ Ссылка ]
---
Disclaimer: The opinions and advice expressed in this webinar are those of the speakers and do not represent the views and opinions of the organizers and National University of Singapore or any of its subsidiaries or affiliates. The information provided in this webinar is for general information purposes only as part of a general discussion on public health. The information is not intended to be a substitute for professional medical advice, diagnoses or treatment; and cannot be relied on in place of consultation with your licensed healthcare provider.
All Rights Reserved.
All of the proceedings of this webinar, including the presentation of scientific papers, are intended for limited publication only, and all property rights in the material presented, including common-law copyright, are expressly reserved to the speaker or NUS. No statement or presentation made is to be regarded as dedicated to the public domain. Any sound reproduction, transcript or other use of the material presented at this course without the permission of the speaker or NUS is prohibited to the full extent of common-law copyright in such material.
